Acadia Pharmaceuticals (ACAD) Non Operating Income (2018 - 2025)
Historic Non Operating Income for Acadia Pharmaceuticals (ACAD) over the last 8 years, with Q3 2025 value amounting to $593000.0.
- Acadia Pharmaceuticals' Non Operating Income rose 295.14% to $593000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.2 million, marking a year-over-year decrease of 115673.08%. This contributed to the annual value of -$13.7 million for FY2024, which is 36844.78% down from last year.
- Per Acadia Pharmaceuticals' latest filing, its Non Operating Income stood at $593000.0 for Q3 2025, which was up 295.14% from $594000.0 recorded in Q2 2025.
- Over the past 5 years, Acadia Pharmaceuticals' Non Operating Income peaked at $4.8 million during Q1 2023, and registered a low of -$15.0 million during Q4 2024.
- In the last 5 years, Acadia Pharmaceuticals' Non Operating Income had a median value of $481000.0 in 2024 and averaged -$40111.1.
- Its Non Operating Income has fluctuated over the past 5 years, first tumbled by 37921.35% in 2022, then soared by 132500.0% in 2023.
- Quarter analysis of 5 years shows Acadia Pharmaceuticals' Non Operating Income stood at $2.2 million in 2021, then dropped by 28.27% to $1.5 million in 2022, then fell by 2.27% to $1.5 million in 2023, then tumbled by 1092.24% to -$15.0 million in 2024, then soared by 103.96% to $593000.0 in 2025.
- Its Non Operating Income stands at $593000.0 for Q3 2025, versus $594000.0 for Q2 2025 and $588000.0 for Q1 2025.